Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology
+$0.14 today
- Market cap
- $56.57M
- Beta
- 2.59
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$6.35
Volume 0.63M
Average 0.42M
CRBP Sales of Investments
Cash received from selling or redeeming investments.
Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments dips below year-ago levels
Q1 FY2026 sales of investments of $33.19M fell 40.4% year over year, behind the +29.2% change in trailing-twelve-month sales of investments. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +11.5% a year.
Context
- Sales of investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -40.4% toward the trailing-twelve-month pace of +29.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 161.46M USD
- Year-over-year change
- +171.4%
- 4-year CAGR
- +84.7%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 161.46M | +171.4% |
| FY2024 | 2024-12-31 | 59.49M | -14.4% |
| FY2023 | 2023-12-31 | 69.53M | -40.3% |
| FY2022 | 2022-12-31 | 116.42M | +738.7% |
| FY2021 | 2021-12-31 | 13.88M | — |
Sales of Investments vs competitors
How CRBP compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +29.2% is the 2nd highest of 9, against a peer median of -41.2%.
- Over three fiscal years its annual growth of +11.5% compares with a peer median of +26.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $459.84M USD | -10.3% | +5.2% | 2496.8% | |
| LTM Mar 2026 | $138.92M USD | +29.2% | +11.5% | — | |
| LTM Mar 2026 | CHF 103.25M CHF | -59.1% | -11.6% | — | |
| LTM Mar 2026 | $82M USD | -28.1% | — | — | |
| LTM Mar 2026 | $67.84M USD | +28.1% | -17.5% | 12922.7% | |
| LTM Mar 2026 | $59.86M USD | -54.2% | +48.2% | 3355.7% | |
| LTM Mar 2026 | $26.75M USD | -65.8% | +107.4% | 844.1% | |
| FY2025 | €13.51M EUR | +40.9% | +65.2% | 484.9% | |
| LTM Mar 2026 | $0 USD | -100.0% | — | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $0 USD | — | — | — |
| Peer median (excluding CRBP) | — | -41.2% | +26.7% | 2496.8% | |
Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (45.64M) | (42.35M) | (44.6M) | (40.21M) | (78.54M) |
| Depreciation & Amortization | 1.64M | 1.49M | 641K | (2.74M) | (1.13M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.48M | 5.72M | 3.47M | 6.15M | 6.29M |
| Change in Working Capital | (15.7M) | (4.02M) | 4.09M | (5.58M) | 9.12M |
| Accounts Receivables | 1.62M | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (5.96M) | (256.84K) | 1.03M | 1.6M | (2.35M) |
| Other Working Capital | (11.36M) | (3.77M) | 3.07M | (7.18M) | 11.47M |
| Other Non-Cash Items | 2.03M | 1.62M | 3.77M | 585K | (229K) |
| Operating Cash Flow | (48.18M) | (37.54M) | (36.1M) | (41.79M) | (64.49M) |
| Capital Expenditures | (54.17K) | (13.45K) | 3 | 0 | (7K) |
| Acquisitions (Net) | 0 | 8.1K | 0 | 0 | 0 |
| Purchases of Investments | (87.27M) | (86.34M) | (33.88M) | (180.8M) | (163.09M) |
| Sales of Investments | 13.88M | 116.42M | 69.53M | 59.49M | 161.46M |
| Other Investing Activities | 23.9K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (73.42M) | 30.07M | 35.64M | (121.31M) | (1.64M) |
| Debt Repayment | 57.78K | (533.62K) | (2.87M) | (15.48M) | 0 |
| Common Stock Issued | 62.59M | 0 | 53.4K | 182.06M | 77.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.82M) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 60.82M | (533.62K) | (2.82M) | 166.58M | 77.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (60.78M) | (8M) | (3.28M) | 3.47M | 11.29M |
| Free Cash Flow | (48.24M) | (37.56M) | (36.1M) | (41.79M) | (64.5M) |
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
Intrinsic Alpha fair value
Locked
Current Price
$2.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.